Instituto de Cardiologia de Santa Catarina
Quick facts
Marketed products
Phase 3 pipeline
- Nitroglycerin II · Cardiovascular
Nitroglycerin releases nitric oxide, which activates guanylate cyclase to increase cGMP levels, causing vasodilation of blood vessels.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Instituto de Cardiologia de Santa Catarina portfolio CI brief
- Instituto de Cardiologia de Santa Catarina pipeline updates RSS
Frequently asked questions about Instituto de Cardiologia de Santa Catarina
What are Instituto de Cardiologia de Santa Catarina's marketed drugs?
Top marketed products include Nitroglycerin I.
What is Instituto de Cardiologia de Santa Catarina's pipeline?
Instituto de Cardiologia de Santa Catarina has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Nitroglycerin II.
Related
- Nitroglycerin I
- Sector hub: All tracked pharma companies